What is the recommended Engerix-B (hepatitis B vaccine) vaccination schedule for different patient populations?

Engerix-B Vaccination Schedules

Standard Adult Schedule (≥20 years)

For healthy adults aged 20 years and older, administer Engerix-B 20 μg (1.0 mL) intramuscularly at 0,1, and 6 months. 1, 2

• This 3-dose series achieves seroprotection (anti-HBs ≥10 mIU/mL) in 79% by month 6 and 96% by month 7, with a geometric mean titer (GMT) of 2,204 mIU/mL among seroconverters 2
• Seroprotection rates exceed 93-100% one month after completing the series in healthy adults 3, 4
• Note that vaccine response declines with age: adults over 40 years achieve only 88% seroprotection with lower GMTs (610 mIU/mL) compared to younger adults 2

Adolescent Schedule (11-19 years)

For adolescents aged 11-19 years, administer Engerix-B 10 μg (0.5 mL) at 0,1, and 6 months. 1, 2

• This achieves 97% seroprotection at month 8 with a GMT of 1,989 mIU/mL 2
• An alternative 20 μg dose produces 99% seroprotection with higher GMT (7,672 mIU/mL), though the clinical significance is unclear 2

Alternative Extended Schedule for Low-Risk Adolescents

For children and adolescents aged 5-16 years at low risk of immediate HBV exposure, you can use an extended schedule of 0,12, and 24 months with 10 μg doses. 5

• This achieves 88.8% seroprotection before the third dose and 98.1% one month after completion 5
• GMTs are slightly lower (3,159 mIU/mL) compared to the standard 0-1-6 month schedule (5,687 mIU/mL), though the clinical relevance is unknown 2, 5

Pediatric Schedule (6 months to 10 years)

For children aged 6 months to 10 years, administer Engerix-B 10 μg at 0,1, and 6 months. 2

• This achieves 98% seroprotection 1-2 months after the third dose with a GMT of 4,023 mIU/mL 2

Infant Schedule

For infants, administer Engerix-B 10 μg at 0,1, and 2 months, followed by a fourth dose at 12 months. 2

• The 0-1-2 month series produces 96% seroprotection by month 4 with a GMT of 210 mIU/mL 2
• The additional dose at 12 months dramatically increases GMT to 2,941 mIU/mL at month 13 2
• Critical pitfall: Do not administer the final dose before 24 weeks of age 6

Accelerated Schedule for Rapid Protection

For adults requiring rapid protection (recent exposure, travelers, neonates of HBV-positive mothers), use the accelerated 4-dose schedule: 0,1,2, and 12 months with 20 μg doses. 1, 2

• This achieves 99% seroprotection by month 3 and maintains protection through month 12 2
• The fourth dose at 12 months is essential for long-term protection, producing a GMT of 9,163 mIU/mL at month 13 2
• Alternative intervals of 0,1,4 months or 0,2,4 months produce similar seroprotection to the standard schedule 1

Immunocompromised and Hemodialysis Patients

For hemodialysis patients and immunocompromised adults aged ≥20 years, administer Engerix-B 40 μg (2.0 mL) at 0,1,2, and 6 months. 7, 1

• This 4-dose regimen achieves 67% seroprotection with a GMT of 93 mIU/mL among seroconverters 2
• This is substantially lower than healthy adults, reflecting the impaired immune response in this population 3
• The 4-dose schedule is superior to the standard 3-dose regimen in hemodialysis patients 2

HIV-Infected Patients

For HIV-infected adults without evidence of past or present HBV infection, administer either 40 μg Recombivax HB on a 3-dose schedule OR 40 μg Engerix-B (administered as 2 doses of 20 μg simultaneously) on a 4-dose schedule at 0,1,2, and 6 months. 7

• Test for anti-HBs response 1-2 months after the third dose or at the next scheduled clinic visit 7

Pregnancy Considerations

Pregnant women requiring hepatitis B vaccination should receive only Engerix-B, Recombivax HB, or Twinrix, as Heplisav-B and PreHevbrio lack sufficient safety data in pregnancy. 1, 6

Managing Interrupted Schedules

If the vaccination schedule is interrupted, never restart the series—simply continue where you left off. 1, 6

• The second and third doses must be separated by ≥8 weeks 1, 6
• The final dose must be administered at least 16 weeks after the first dose 6
• Minimum intervals: 4 weeks between doses 1 and 2; 8 weeks between doses 2 and 3; 16 weeks between doses 1 and 3 1, 6
• Doses administered ≤4 days before the minimum interval are considered valid 1
• There is no maximum interval between doses—delayed doses do not require restarting 6

Post-Vaccination Testing

Routine serologic testing is not necessary for most adults, but test for anti-HBs 1-2 months after series completion for healthcare workers, public safety workers, and other high-risk groups. 1

• Protective level is anti-HBs ≥10 mIU/mL 1
• Pre-vaccination testing is not required and should not be a barrier to vaccination 1

Common Pitfalls to Avoid

• Do not restart the series if doses are delayed—there is no maximum interval between doses 6
• Do not use Heplisav-B or PreHevbrio in pregnant women, hemodialysis patients, or children 1, 6
• Do not assume lower response in older adults means failure—88% still achieve protection, but consider higher doses or additional doses if initial response is inadequate 2
• Do not forget the fourth dose at 12 months when using accelerated schedules—it is essential for long-term protection 2